title: The therapeutic potential of cannabinoids for movement disorders.
abstract: There is growing interest in the therapeutic potential of marijuana (cannabis) and cannabinoid-based chemicals within the medical community and, particularly, for neurological conditions. This interest is driven both by changes in the legal status of cannabis in many areas and increasing research into the roles of endocannabinoids within the central nervous system and their potential as symptomatic and/or neuroprotective therapies. We review basic science as well as preclinical and clinical studies on the therapeutic potential of cannabinoids specifically as it relates to movement disorders. The pharmacology of cannabis is complex, with over 60 neuroactive chemicals identified to date. The endocannabinoid system modulates neurotransmission involved in motor function, particularly within the basal ganglia. Preclinical research in animal models of several movement disorders have shown variable evidence for symptomatic benefits, but more consistently suggest potential neuroprotective effects in several animal models of Parkinson's (PD) and Huntington's disease (HD). Clinical observations and clinical trials of cannabinoid-based therapies suggests a possible benefit of cannabinoids for tics and probably no benefit for tremor in multiple sclerosis or dyskinesias or motor symptoms in PD. Data are insufficient to draw conclusions regarding HD, dystonia, or ataxia and nonexistent for myoclonus or RLS. Despite the widespread publicity about the medical benefits of cannabinoids, further preclinical and clinical research is needed to better characterize the pharmacological, physiological, and therapeutic effects of this class of drugs in movement disorders.
authors: Movement Disorders Center, Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.
authors: Benzi
authors: B
authors: Kluger
authors: Piera
authors: P
authors: Triolo
authors: Wallace
authors: W
authors: Jones
authors: Joseph
authors: J
authors: Jankovic
mesh_terms: D000818:Animals; D001479:Basal Ganglia / Q000378:metabolism; D002186:Cannabinoids / Q000627:therapeutic use*; D006801:Humans; D009069:Movement Disorders / Q000188:drug therapy* / Q000473:pathology; D018696:Neuroprotective Agents / Q000627:therapeutic use*
chemical_list: D002186:Cannabinoids; D018696:Neuroprotective Agents
keywords: Huntington's disease; Parkinson's disease; cannabinoids; cannabis; movement disorders
references: Chem Biodivers. 2007 Aug;4(8):1770-804
references: 17712819
references: Neuropathol Appl Neurobiol. 2012 Oct;38(6):535-47
references: 22236282
references: Nature. 2000 Mar 2;404(6773):84-7
references: 10716447
references: Neurosci Lett. 2008 Jun 13;438(1):10-3
references: 18457923
references: Br J Pharmacol. 2014 Aug;171(16):3908-17
references: 24762058
references: Pharmacol Toxicol. 2003 Aug;93(2):66-70
references: 12899667
references: Ann Neurol. 2005 May;57(5):777-9
references: 15852389
references: Ann Neurol. 1983 Jun;13(6):669-71
references: 6309074
references: ACS Chem Neurosci. 2012 May 16;3(5):400-6
references: 22860209
references: Neurology. 2004 Oct 12;63(7):1245-50
references: 15477546
references: Brain Res. 2007 Feb 23;1134(1):162-70
references: 17196181
references: Psychopharmacology (Berl). 2001 Jun;156(1):79-85
references: 11465637
references: Mol Neurobiol. 2007 Aug;36(1):82-91
references: 17952653
references: Mov Disord. 1998 Nov;13(6):871-6
references: 9827609
references: Anat Cell Biol. 2011 Jun;44(2):135-42
references: 21829757
references: Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3149-56
references: 25024177
references: Eur J Neurosci. 2007 Aug;26(4):843-51
references: 17672854
references: CNS Neurol Disord Drug Targets. 2009 Dec;8(6):440-50
references: 19839933
references: Eur J Neurosci. 2009 Jun;29(11):2177-86
references: 19490092
references: Behav Pharmacol. 2013 Dec;24(8):640-52
references: 24196024
references: J Neurol Neurosurg Psychiatry. 2014 May;85(5):573-5
references: 24259592
references: J Neurosci. 2002 Aug 15;22(16):6900-7
references: 12177188
references: Neurosci Res. 2012 Mar;72(3):236-42
references: 22192465
references: Int J Neurosci. 1986 Nov;30(4):277-82
references: 3793381
references: Drug Alcohol Depend. 2014 Mar 1;136:158-61
references: 24440049
references: Pharmacol Biochem Behav. 1981 Nov;15(5):779-83
references: 6273940
references: Neuron. 2012 Oct 4;76(1):70-81
references: 23040807
references: J Clin Pharm Ther. 2014 Oct;39(5):564-6
references: 24845114
references: J Pharmacol Exp Ther. 2007 Oct;323(1):318-26
references: 17630359
references: Brain Res. 2010 Dec 2;1363:40-8
references: 20888328
references: Neurobiol Dis. 2005 Jun-Jul;19(1-2):96-107
references: 15837565
references: Proc Natl Acad Sci U S A. 1989 Dec;86(23):9584-7
references: 2556719
references: Mov Disord. 2002 Nov;17(6):1180-7
references: 12465055
references: Neurology. 2007 Jul 17;69(3):306-9
references: 17636069
references: Glia. 2009 Aug 15;57(11):1154-67
references: 19115380
references: J Psychopharmacol. 2014 Nov;28(11):1088-98
references: 25237116
references: J Nucl Med. 2010 Sep;51(9):1413-7
references: 20720046
references: Brain Struct Funct. 2015 Sep;220(5):2721-38
references: 24972960
references: Arch Gen Psychiatry. 1995 Mar;52(3):219-29
references: 7872850
references: Neuropsychopharmacology. 2003 Feb;28(2):384-8
references: 12589392
references: Cochrane Database Syst Rev. 2009;(4):CD006565
references: 19821373
references: Brain Res. 2002 Mar 8;929(2):236-42
references: 11864629
references: Pharmacotherapy. 2013 Feb;33(2):195-209
references: 23386598
references: Mov Disord. 2004 Sep;19(9):1102-6
references: 15372606
references: Brain. 2009 Nov;132(Pt 11):3152-64
references: 19805493
references: Neurotherapeutics. 2014 Jan;11(1):117-27
references: 24282121
references: CNS Neurosci Ther. 2011 Dec;17(6):637-44
references: 20875047
references: Brain Res. 2004 May 8;1007(1-2):152-9
references: 15064146
references: Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jul 2;38(1):21-9
references: 22265889
references: Recent Pat CNS Drug Discov. 2007 Jun;2(2):131-9
references: 18221224
references: J Clin Pharmacol. 2013 Jul;53(7):680-90
references: 23754596
references: J Psychopharmacol. 1993 Jan;7(4):389-91
references: 22291003
references: Nature. 2007 Feb 8;445(7128):643-7
references: 17287809
references: JAMA. 2014 May;311(20):2053-4
references: 24828256
references: Behav Brain Res. 2009 Nov 5;203(2):304-7
references: 19414037
references: Vitam Horm. 2009;81:389-419
references: 19647120
references: Mov Disord. 2003 Feb;18(2):138-49
references: 12539206
references: J Neurosci Res. 2011 Sep;89(9):1509-18
references: 21674569
references: Mov Disord. 2009 Nov 15;24(15):2254-9
references: 19845035
references: Lancet Neurol. 2014 Jan;13(1):100-12
references: 24331796
references: J Neural Transm (Vienna). 2003 Nov;110(11):1279-88
references: 14628192
references: Behav Neurol. 2013;27(1):119-24
references: 23187140
references: Neurol Res. 2010 Jun;32(5):451-9
references: 20307378
references: Brain Res. 2005 Jul 19;1050(1-2):210-6
references: 15975564
references: Front Pharmacol. 2012 Jun 12;3:110
references: 22701427
references: J Thorac Oncol. 2008 Dec;3(12):1398-403
references: 19057263
references: Eur J Pharmacol. 2002 Nov 15;454(2-3):145-51
references: 12421641
references: J Neurochem. 2003 May;85(4):1018-25
references: 12716433
references: Brain Res. 2006 Aug 30;1107(1):199-205
references: 16822488
references: FEBS J. 2013 May;280(9):1918-43
references: 23551849
references: Mov Disord. 1999 Nov;14(6):1038-40
references: 10584686
references: J Psychopharmacol. 2009 Nov;23(8):979-83
references: 18801821
references: Science. 2005 Oct 14;310(5746):329-32
references: 16224028
references: Clin Neuropharmacol. 2014 Mar-Apr;37(2):41-4
references: 24614667
references: BMC Neurosci. 2010;11:44
references: 20346144
references: Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):133-44
references: 19285266
references: J Neuropsychiatry Clin Neurosci. 2006 Fall;18(4):553-4
references: 17135385
references: Pharmacol Res. 2009 Aug;60(2):77-84
references: 19559360
references: Synapse. 2002 Apr;44(1):23-35
references: 11842443
references: Am J Psychiatry. 1999 Mar;156(3):495
references: 10080574
references: Psychiatry Res. 2011 Dec 30;190(2-3):382
references: 21664699
references: Neurology. 2004 Apr 13;62(7):1105-9
references: 15079008
references: Tremor Other Hyperkinet Mov (N Y). 2014 Aug 27;4:253
references: 25243097
references: Mov Disord. 2004 Jun;19(6):708-9
references: 15197714
references: Mov Disord. 2002 Jan;17(1):145-9
references: 11835452
references: Nat Rev Immunol. 2005 May;5(5):400-11
references: 15864274
references: Pharmacogenomics J. 2005;5(2):135-41
references: 15668727
references: Handb Exp Pharmacol. 2005;(168):445-77
references: 16596784
references: Neuroreport. 2004 Oct 25;15(15):2375-9
references: 15640759
references: Br J Pharmacol. 2011 Aug;163(7):1495-506
references: 21323909
references: Drug Alcohol Depend. 2012 Jun;123 Suppl 1:S99-S104
references: 22572210
references: Neuroreport. 2003 May 6;14(6):813-6
references: 12858038
references: Eur Neuropsychopharmacol. 2008 May;18(5):383-9
references: 18222654
references: Eur Neuropsychopharmacol. 2006 Jan;16(1):7-18
references: 16006105
references: Eur J Pharmacol. 1994 Nov 3;264(3):371-7
references: 7698178
references: Subst Abus. 2013;34(1):70-2
references: 23327506
references: J Neurol Neurosurg Psychiatry. 1990 May;53(5):436
references: 2351975
references: Neurosci Lett. 1998 Jun 5;248(3):171-4
references: 9654336
references: Mov Disord. 2005 Jan;20(1):113-5
references: 15390041
references: Br J Pharmacol. 2007 Nov;152(5):576-82
references: 17704824
references: Lancet. 2003 Nov 8;362(9395):1517-26
references: 14615106
references: Int J Drug Policy. 2015 Feb;26(2):135-42
references: 25168081
references: Trends Pharmacol Sci. 2009 Mar;30(3):156-63
references: 19233486
references: Neuroreport. 2001 Jul 20;12(10):2125-9
references: 11447320
references: Br J Pharmacol. 2010 Jun;160(3):747-61
references: 20590577
references: Br J Psychiatry. 2001 Feb;178:107-15
references: 11157423
references: Neuroscience. 2010 Sep 29;170(1):324-36
references: 20600638
references: J Neurochem. 2003 Mar;84(5):1097-109
references: 12603833
references: Eur J Neurosci. 2001 Dec;14(11):1827-32
references: 11860478
references: Clin Neuropharmacol. 2004 May-Jun;27(3):108-10
references: 15190231
references: Neuroscience. 2000;97(3):505-19
references: 10828533
references: Neurology. 2001 Dec 11;57(11):2108-11
references: 11739835
references: Expert Opin Drug Saf. 2011 Sep;10(5):675-85
references: 21542664
references: Neurology. 2014 Apr 29;82(17):1556-63
references: 24778283
references: Acta Psychiatr Scand. 1998 Dec;98(6):502-6
references: 9879795
references: J Clin Psychopharmacol. 1988 Dec;8(6):444-5
references: 3235704
references: Mov Disord. 2014 Aug;29(9):1097-9
references: 24976412
references: J Clin Psychopharmacol. 2010 Apr;30(2):190-2
references: 20520294
references: FASEB J. 2000 Jul;14(10):1432-8
references: 10877836
references: J Neurochem. 1993 Nov;61(5):1705-12
references: 7901331
references: Neuropsychopharmacology. 2004 Jun;29(6):1134-42
references: 15010694
references: Trends Neurosci. 1998 Dec;21(12):521-8
references: 9881850
references: Neurosci Res. 2008 Aug;61(4):404-11
references: 18538428
references: Neurobiol Dis. 2005 Apr;18(3):591-601
references: 15755685
references: Exp Neurol. 2007 Nov;208(1):110-9
references: 17900568
references: J Pain Symptom Manage. 2002 Jul;24(1):4-6
references: 12183086
references: Eur Neurol. 1997;38(1):44-8
references: 9252798
references: J Pharmacol Exp Ther. 2011 Feb;336(2):423-30
references: 20966038
references: Neuroscience. 2008 Jan 2;151(1):104-10
references: 18068305
references: N Engl J Med. 2014 Jun 5;370(23):2219-27
references: 24897085
references: J Neurol. 1989 Feb;236(2):120-2
references: 2709054
references: Epilepsia. 2014 Jun;55(6):791-802
references: 24854329
references: J Clin Psychiatry. 2003 Apr;64(4):459-65
references: 12716250
references: Life Sci. 2000;66(6):485-94
references: 10794065
references: Pharmacol Biochem Behav. 1991 Nov;40(3):701-8
references: 1839644
references: Neuropharmacology. 2006 Oct;51(5):1004-12
references: 16895732
references: FASEB J. 2005 Jul;19(9):1140-2
references: 15894565
references: Neuropharmacology. 2011 Feb-Mar;60(2-3):418-22
references: 21029743
references: Brain Res. 2006 Feb 16;1073-1074:209-19
references: 16412990
references: Pharmacopsychiatry. 2002 Mar;35(2):57-61
references: 11951146
references: Pharmacol Rev. 2002 Jun;54(2):161-202
references: 12037135